Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel versus docetaxel + lapatinib in recurrent or metastatic SCCHN
NL-OMON32481Phase 2Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Docetaxel with Docetaxel + lapatinib (2 arms). Primary endpoint: Clinical benefit at week 8. Planned start Dec 2008; status: not yet recruiting.
02
Drugs
docetaxellapatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON32481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32481.